vebreltinib

Biomarkers

Sponsors

Industry sponsors leading active biomarker-selected trials of vebreltinib.

1. Avistone Biotechnology 3
2. Beijing Pearl Biotechnology 2
3. Apollomics 1

Trials

13 of 13 trials shown

1. Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

   Not yet recruiting Phase 3 Avistone Biotechnology Started 2025Primary completion 2027-12 NCT06970782

   vebreltinibPLB1004pemetrexedcarboplatincisplatin

   Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

   EGFR exon 19 deletion / L858RNon-Small-Cell Lung Cancer

2. A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

   Recruiting Phase 3 Beijing Pearl Biotechnology Started 2023Primary completion 2026-09 NCT05989542

   vebreltinib

   The presence of MET exon 14 jump mutation was confirmed by the NGS test in the central laboratory, and the 'Combined …

   MET exon 14 skippingNon-small Cell Lung Cancer

3. A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

   Active, not recruiting Phase 2/3 Beijing Pearl Biotechnology Started 2018Primary completion 2023-04 NCT06105619

   vebreltinibtemozolomidecisplatinetoposide

   A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

   IDH1/2 mutationGlioblastoma

4. Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

   Recruiting Phase 1/2 Second Affiliated Hospital of Nanchang University Started 2026Primary completion 2027-12 NCT07655622

   vebreltinibfurmonertinib

   …ed/metastatic disease Histologically or cytologically confirmed EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R point mutation)

   EGFR exon 19 deletion / L858RNon-Small-Cell Lung Cancer

5. Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

   Recruiting Phase 1/2 Peking University Cancer Hospital & Institute Started 2025Primary completion 2027-04 NCT07087223

   vebreltinibfurmonertinib

   Documented EGFR sensitive mutations (exon 19 deletion or exon 21 L858R mutation).

   EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer NSCLC

6. Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer

   Not yet recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai Started 2025Primary completion 2027-09 NCT07153770

   vebreltinib

   MET exon 14 skipping mutation (NGS results from tissue or blood sample certified by CLIA or CAP).

   MET exon 14 skippingNSCLC, MET Exon 14 Mutation, MET Activating Mutation

7. Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

   Not yet recruiting Phase 2 Fudan University Started 2025Primary completion 2027-09 NCT07156604

   vebreltinib

   NGS gene testing confirmed MET exon 14 skipping mutations (NGS results from tissue or blood samples certified by CLIA or CAP-app…

   MET exon 14 skippingNSCLC, Neoadjuvant Therapy

8. Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

   Recruiting Phase 2 Avistone Biotechnology Started 2024Primary completion 2026-10 NCT06574347

   vebreltinibosimertinib FDA EUPLB1004

   Patients with previously untreated, EGFRm-positive (exon 19 deletion or L858R) and MET overexpression (IHC 3+) .

   EGFR exon 19 deletion / L858RNon-Small-Cell Lung Cancer

9. Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

   Active, not recruiting Phase 2 National Cancer Center Started 2024Primary completion 2026-09 NCT06827145

   vebreltinibosimertinib FDA EU

   4.EGFR 21 L858R mutation.

   EGFR exon 19 deletion / L858RNon-Small-Cell Lung Cancer

10. Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

    Not yet recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai Started 2024Primary completion 2029-11 NCT06644313

    vebreltinib

    … gene testing confirmed MET alterations, which include the following two types: Cohort 1: MET exon 14 skipping mutations (NGS results from tissue or blood samples certified by CLIA or CAP-app…

    MET exon 14 skippingStatus may be outdated, last updated 2024-10-16Potentially Resectable MET-altered Non-Small Cell Lung Cancer

11. Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

    Recruiting Phase 1/2 Avistone Biotechnology Started 2023Primary completion 2026-12 NCT06343064

    vebreltinibPLB1004

    EGFR mutations, including exon 19 deletion and exon 21 L858R.

    EGFR exon 19 deletion / L858RNon-Small-Cell Lung Cancer

12. Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

    Active, not recruiting Phase 1/2 Washington University School of Medicine Started 2022Primary completion 2027-01 NCT04743505

    vebreltinibosimertinib FDA EU

    …ncer, or locally advanced disease that is not amendable for curative intent therapy, with TKI-sensitive EGFR mutation through CLIA certified lab.

    EGFR exon 19 deletion / L858RMetastatic Non Small Cell Lung Cancer

13. APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

    Recruiting Phase 2 Apollomics Started 2017Primary completion 2026-03 NCT03175224

    vebreltinib

    …C MET inhibitor naive in first line: Histologically or cytologically confirmed NSCLC with Exon 14 skipping mutations

    MET exon 14 skippingSolid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer

No trials match these filters.